Literature DB >> 22363134

Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.

Ana Abajo1, Nerea Bitarte, Ruth Zarate, Valentina Boni, Ines Lopez, Marisol Gonzalez-Huarriz, Javier Rodriguez, Eva Bandres, Jesus Garcia-Foncillas.   

Abstract

AIM: To investigate the angiogenesis-related protein expression profile characterizing metastatic colorectal cancer (mCRC) with the aim of identifying prognostic markers.
METHODS: The expression of 44 angiogenesis-secreted factors was measured by a novel cytokine antibody array methodology. The study evaluated vascular endothelial growth factor (VEGF) and its soluble vascular endothelial growth factor receptor (sVEGFR)-1 protein levels by enzyme immunoassay (EIA) in a panel of 16 CRC cell lines. mRNA VEGF and VEGF-A isoforms were quantified by quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) and vascular endothelial growth factor receptor (VEGFR)-2 expression was analyzed by flow cytometry.
RESULTS: Metastasis-derived CRC cell lines expressed a distinctive molecular profile as compared with those isolated from a primary tumor site. Metastatic CRC cell lines were characterized by higher expression of angiogenin-2 (Ang-2), macrophage chemoattractant proteins-3/4 (MCP-3/4), matrix metalloproteinase-1 (MMP-1), and the chemokines interferon γ inducible T cell α chemoattractant protein (I-TAC), monocyte chemoattractant protein I-309, and interleukins interleukin (IL)-2 and IL-1α, as compared to primary tumor cell lines. In contrast, primary CRC cell lines expressed higher levels of interferon γ (IFN-γ), insulin-like growth factor-1 (IGF-1), IL-6, leptin, epidermal growth factor (EGF), placental growth factor (PlGF), thrombopoietin, transforming growth factor β1 (TGF-β1) and VEGF-D, as compared with the metastatic cell lines. VEGF expression does not significantly differ according to the CRC cellular origin in normoxia. Severe hypoxia induced VEGF expression up-regulation but contrary to expectations, metastatic CRC cell lines did not respond as much as primary cell lines to the hypoxic stimulus. In CRC primary-derived cell lines, we observed a two-fold increase in VEGF expression between normoxia and hypoxia as compared to metastatic cell lines. CRC cell lines express a similar pattern of VEGF isoforms (VEGF₁₂₁, VEGF₁₆₅ and VEGF₁₈₉) despite variability in VEGF expression, where the major transcript was VEGF₁₂₁. No relevant expression of VEGFR-2 was found in CRC cell lines, as compared to that of human umbilical vein endothelial cells and sVEGFR-1 expression did not depend on the CRC cellular origin.
CONCLUSION: A distinct angiogenesis-related expression pattern characterizes metastatic CRC cell lines. Factors other than VEGF appear as prognostic markers and intervention targets in the metastatic CRC setting.

Entities:  

Keywords:  Angiogenesis; Biomarkers; Colorectal cancer metastasis; Cytokine-antibody array; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2012        PMID: 22363134      PMCID: PMC3281220          DOI: 10.3748/wjg.v18.i7.637

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

Authors:  Aihua Li; Seema Dubey; Michelle L Varney; Bhavana J Dave; Rakesh K Singh
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

3.  I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo.

Authors:  G Bernardini; G Spinetti; D Ribatti; G Camarda; L Morbidelli; M Ziche; A Santoni; M C Capogrossi; M Napolitano
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 4.  Clinical implications of circulating angiogenic factors in cancer patients.

Authors:  R T Poon; S T Fan; J Wong
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

Review 5.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

6.  Effect of p53 status on tumor response to antiangiogenic therapy.

Authors:  Joanne L Yu; Janusz W Rak; Brenda L Coomber; Daniel J Hicklin; Robert S Kerbel
Journal:  Science       Date:  2002-02-22       Impact factor: 47.728

7.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Authors:  Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

Authors:  Astrid Lièvre; Emmanuelle Samalin; Emmanuel Mitry; Eric Assenat; Christine Boyer-Gestin; Céline Lepère; Jean-Baptiste Bachet; Fabienne Portales; Jean-Nicolas Vaillant; Marc Ychou; Philippe Rougier
Journal:  BMC Cancer       Date:  2009-09-28       Impact factor: 4.430

View more
  14 in total

1.  Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Authors:  Marine Jary; Dewi Vernerey; Thierry Lecomte; Erion Dobi; François Ghiringhelli; Franck Monnien; Yann Godet; Stefano Kim; Olivier Bouché; Serge Fratte; Anthony Gonçalves; Julie Leger; Lise Queiroz; Olivier Adotevi; Franck Bonnetain; Christophe Borg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01-12       Impact factor: 4.254

2.  Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis.

Authors:  Sean Maroney; Carlos Chavez de Paz; Mark E Reeves; Carlos Garberoglio; Elizabeth Raskin; Maheswari Senthil; Jukes P Namm; Naveenraj Solomon
Journal:  J Gastrointest Surg       Date:  2017-11-09       Impact factor: 3.452

3.  Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Wafaey Gomaa; Abdelbaset Buhmeida; Yousif Qari; Mohammad Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Tumour Biol       Date:  2014-06-09

4.  Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer.

Authors:  Lui Ng; Timothy Ming-Hun Wan; Colin Siu-Chi Lam; Ariel Ka-Man Chow; Sunny Kit-Man Wong; Johnny Hon-Wai Man; Hung-Sing Li; Nathan Shiu-Man Cheng; Ryan Chung-Hei Pak; Alvin Ho-Kwan Cheung; Thomas Chung-Cheung Yau; Oswens Siu-Hung Lo; Dominic Chi-Chung Foo; Jensen Tung-Chung Poon; Ronnie Tung-Ping Poon; Roberta Wen-Chi Pang; Wai-Lun Law
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 5.  Biology of colorectal cancer.

Authors:  Francisco Arvelo; Felipe Sojo; Carlos Cotte
Journal:  Ecancermedicalscience       Date:  2015-04-09

6.  Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

Authors:  Francois Ghiringhelli; Damien Bichard; Samuel Limat; Veronique Lorgis; Julie Vincent; Christophe Borg; Julie Berthou; David Orry; Pablo Ortega-Deballon; Zaher Lakkis; Olivier Facy; Bruno Heyd; Patrick Rat; Virginie Nerich; Sylvain Ladoire
Journal:  Ann Surg Oncol       Date:  2014-01-14       Impact factor: 5.344

7.  Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.

Authors:  A J C Pommier; R Shaw; S K M Spencer; S R Morgan; P M Hoff; J D Robertson; S T Barry; J M Jürgensmeier
Journal:  Br J Cancer       Date:  2014-08-14       Impact factor: 7.640

8.  Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Authors:  Krittiya Korphaisarn; Jonathan M Loree; Van Nguyen; Ryanne Coulson; Vijaykumar Holla; Beate C Litzenburger; Ken Chen; Gordon B Mills; Dipen M Maru; Funda Meric-Bernstan; Kenna R Mills Shaw; Scott Kopetz
Journal:  Oncotarget       Date:  2017-06-03

9.  NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway.

Authors:  Yanan Gu; Hefen Yu; Chengcheng Hao; Tracey A Martin; Rachel Hargest; Junqi He; Shan Cheng; Wen G Jiang
Journal:  Oncotarget       Date:  2017-01-31

10.  Correlation Between IGFs-Related Proteins Expression and Incidence of Colorectal Cancer in Diabetic Patients and Related Mechanisms.

Authors:  Xu Han; Sufang Hou; Aige Yang
Journal:  Med Sci Monit       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.